Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission

American Journal of Hematology

Volumn 88, Issue 8, 2013, Pages 634-641

  Eom, Ki Seong ^a   Shin, Seung Hwan ^a   Yoon, Jae Ho ^a   Yahng, Seung Ah ^a   Lee, Sung Eun ^a   Cho, Byung Sik ^a   Kim, Yoo Jin ^a   Kim, Hee Je ^a   Min, Chang Ki ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Park, Chong Won ^a   Lee, Seok ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; IDARUBICIN; IMATINIB; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; TACROLIMUS; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GROUPS BY AGE; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84880802526     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23465     Document Type: Article

References (37)

1. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute Lymphoblastic leukemia. J Clin Oncol 2002;20:2464-2471.
2. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;9:863-871.
3. Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia 2002;16:1259-1266.
4. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-2801.
5. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004;104:3028-3037.
6. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-4086.
7. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767.
8. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer 2006;106:2657-2663.
9. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827-1833.
10. Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison. Blood 2009;113:1375-1382.
11. Arnold R, Massenkeil G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002;16:2423-2428.
12. Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003;88:555-560.
13. Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: A retrospective study of 33 patients. Bone Marrow Transplant 2005;35:549-556.
14. Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008;93:303-306.
15. Stein AS, Palmer JM, O'Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009;15:1407-1414.
16. Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009;113:2902-2905.
17. Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96:1113-1120.
18. Cho BS, Lee S, Kim YJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: Results of a prospective phase 2 study. Leukemia 2009;23:1763-1770.
19. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010;116:4439-4443.
20. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010;116:366-374.
21. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449-3457.
22. Lee S, Kim YJ, Chung NG, et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009;115:561-570.
23. Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012;26:2367-2374.
24. Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: Antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:1083-1094.
25. Lee S, Chung NG, Cho BS, et al. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia 2010;24:2110-2119.
26. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-3197.
27. Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: Results of Southwest Oncology Group 9400 study. Blood 2008;111:2563-2572.
28. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
29. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
30. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.
31. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
32. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999;94:456-509.
33. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-4407.
34. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460-466.
35. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469-1477.
36. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007;109:1408-1413.
37. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010;28:3644-3652.